Abstract
Memantine is a blocker of Ca2+-permeable glutamate and nicotinic acetylcholine receptors (nAChR). We investigated the action of memantine on cholinergic synaptic transmission at cochlear outer hair cells (OHCs). At this inhibitory synapse, hyperpolarization of the postsynaptic cell results from opening of SK-type Ca2+-activated K+ channels via a highly Ca2+-permeable nAChR containing the α9 subunit. We show that inhibitory postsynaptic currents recorded from OHCs were reversibly blocked by memantine with an IC50 value of 16 μM. RT-PCR revealed that a newly cloned nAChR subunit, α10, is expressed in OHCs. In contrast to homomeric expression, coexpression of α9 and α10 subunits in Xenopus laevis oocytes resulted in robust acetylcholine-induced currents, indicating that the OHC nAChR may be an α9/α10 heteromer. Accordingly, nAChR currents evoked by application of the ligand to OHCs and currents through α9/α10 were blocked by memantine with a similar IC50value of about 1 μM. Memantine block of α9/α10 was moderately voltage dependent. The lower efficacy of memantine for inhibition of inhibitory postsynaptic currents (IPSCs) most probably results from a blocking rate that is slow with respect to the short open time of the receptor channels during an IPSC. Thus, synaptic transmission in OHCs is inhibited by memantine block of Ca2+ influx through nAChRs. Importantly, prolonged receptor activation and consequently massive Ca2+ influx, as might occur under pathological conditions, is blocked at low micromolar concentrations, whereas the fast IPSCs initiated by short receptor activation are only blocked at concentrations above 10 μM.
Abbreviations
- memantine
- 3,5-dimethyl-1-adamantanamine
- NMDA
- N-methyl-d-aspartate
- OHC
- outer hair cell
- nAChR
- nicotinic acetylcholine receptor
- BAPTA
- 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
- IPSC
- inhibitory postsynaptic current
- ACh
- acetylcholine
- RT-PCR
- reverse transcriptase-polymerase chain reaction
- Received January 25, 2001.
- Accepted April 5, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|